Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure

Nephron - Physiology

Volumn 107, Issue 1, 2007, Pages

  Wrong, Oliver ^a   Harland, Clive ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Harlandwater Services   (United Kingdom)

Author keywords

Anion exchange resin; Renal failure; Short chain fatty acids; Van der Waals; Weak base

Indexed keywords

ACRYLIC POLYAMINE RESIN; AMINOSALICYLIC ACID; ANION EXCHANGE RESIN; COLESTILAN; COLESTIPOL; COLESTYRAMINE; DOWEX; DRUG CARRIER; ETHENYLBENZENE POLYETHYLENEAMINE RESIN; FORMALDEHYDE; PHOSPHATE; PLACEBO; POLACRILIN; POLYAMINE; SEVELAMER; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ACIDOSIS; ANION EXCHANGE; CHRONIC KIDNEY FAILURE; CONCENTRATION RESPONSE; DRUG COST; FECES; GASTROINTESTINAL TRACT; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; METABOLIC BALANCE; NONHUMAN; PHOSPHATE EXCRETION; PRIORITY JOURNAL; SHORT SURVEY; STOMACH PH; STOMACH ULCER; TREATMENT DURATION;

ACIDOSIS; ANION EXCHANGE RESINS; ANIONS; BILE; GASTROINTESTINAL TRACT; HUMANS; KIDNEY FAILURE, CHRONIC; OSMOLAR CONCENTRATION; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES;

EID: 34548457654     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106568     Document Type: Short Survey

References (85)

1. Ansell D, Feest T, Rao AVR, Williams A, Winearls C: Eighth Annual report. Bristol, UK Renal Registry, 2005.
2. Block GA, Klassen PS, Lazarus GM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
3. Qunibi WY: Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 2004;66(suppl 90):S8-S12.
4. London GM, Marchais SJ, Guérin AP, Métivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525-531.
5. Jean G, Chazot C, Charra B: Hyperphosphataemia and related mortality. Nephrol Dial Transplant 2006;21:273-280.
6. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
7. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005;16:3736-3741.
8. Grassman A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004; global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593.
9. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Polyallylamine hydrochloride (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
10. Holmes-Farley SR, Mandeville WH, Ward J, Miller KL: Design and characterization of sevelamer hydrochloride: a novel phosphate-binding pharmaceutical. J Macromol Sci Pure Appl Chem 1999;A36:1085-1091.
11. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI: Effect of RenaGel®, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphate excretion in rats. Nephrol Dial Transplant 1997;12:961-964.
12. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel®, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-1644.
13. Helfferich F: Ion Exchange. New York, McGraw-Hill, 1962.
14. Harland CE: Ion Exchange: Theory and Practice, ed 2. Cambridge, Royal Society of Chemistry, 1994.
15. Dorfner K: Synthetic ion exchange resins; in Dorfner K (ed): Ion Exchangers. Berlin, de Gruyter, 1991, pp 189-396.
16. Wheaton RM, Hatch MJ: Synthesis of ion exchange resins; in Marinsky JA (ed): Ion Exchange: A Series of Advances, vol 2. New York, Dekker, 1991, pp 191-234.
17. Martin GJ, Wilkinson J: The neutralization of gastric acidity with anion exchange resins. Gastroenterology 1946;6:315-323.
18. Wirts CW, Rehfuss ME: A study of the effect of an anion exchange resin on gastric and duodenal secretions and gastric emptying. J Clin Invest 1950;29:37-45.
19. Greenman L, Frey WA, Lewis RE, Sakol MJ, Danowski TS: Biochemical changes in serum and feces during ingestion of carboxylic, sulphonic and anion-exchange resins. J Lab Clin Med 1953;41:236-247.
20. Hurst PE, Morrison RBI, Timoner J, Metcalfe-Gibson A, Wrong O: The effect of oral anion exchange resins on faecal anions. Comparison with calcium salts and aluminium hydroxide. Clin Sci 1963;24:187-200.
21. Bergen SS, Van Italie YB, Tennent DM, Sebrell WH: Effect of an anion exchange resin on serum cholesterol in man. Proc Soc Exp Biol Med 1959;102:676-678.
22. Carey JB, Williams G: Relief of pruritus of jaundice with a bile-acid sequestering resin. J Am Med Assoc 1961;176:432-435.
23. Smith LH, Fromm H, Hofmann AF: Acquired hyperoxaluria, nephrolithiasis and intestinal disease. New Engl J Med 1972;286:1371-1375.
24. Clark WM: Topics in Physical Chemistry. Baltimore, Williams and Wilkins, 1952.
25. Hazell T: Minerals in foods: dietary sources, chemical forms, interactions and bioavailability. World Rev Nutr Diet 1985;46:1-123.
26. Calvo MS, Park YK: Changing phosphorus content of the US diet: potential for adverse effect on bone. J Nutr 1996;126:1168S-1180S.
27. Hunt CD, Meacham SL: Aluminum, boron, calcium, copper, iron, magnesium, manganese, molybdenum, phosphorus, potassium, sodium and zinc concentrations in common western foods and estimated daily intakes of infants, toddlers, and male and female adolescents, adults and seniors in the United States. J Am Diet Assoc 2001;101:1058-1060.
28. Rimington C, Kay HD: Some phosphorus compounds of milk. 2. The liberation of phosphorus from caseinogen by enzymes and other agents. Biochem J 1926;20:777-790.
29. Karr WG, Abbott WO: Intubation studies on the human small intestine. 4. Chemical characteristics of the intestinal contents in the fasting state and as influenced by the administration of acids, of alkalis, and of water. J Clin Invest 1935;14:893-900.
30. Altman PL, Dittmer DS: Metabolism. Bethesda, Federation of American Societies for Experimental Biology, 1968.
31. Lura HE: Investigations of the salivary phosphates and phosphatases. J Dent Res 1947;26:202-224.
32. Blum M, Zurkowsky S, Gilad J, Aviram A: Salivary phosphate and calcium concentrations in uraemia. Clin Nephrol 1979;12:191-192.
33. Savica V, Calò LA, Caldarera R, Cavaleri A, Granata A, Santoro D, Savica R, Muraca U, Mallamace A, Bellinghieri G: Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol 2007;105:52-55.
34. Rudd GV: Studies on composition of gastric juice. Part I. Med J Aust 1934;1:431-436.
35. Kogut B, Matzner MJ, Sobel AE: A study of external pancreatic secretions in man. J Clin Invest 1936;15:393-396.
36. 3. J Clin Invest 1980;65:1326-1331.
37. Danisi G, Murer H: Inorganic phosphate absorption in small intestine; in Handbook of Physiology, ed 2, section 6: The Gastrointestinal System, vol 4; Schultz SG, Field M, Frizzell RA, Rauner BB (sect eds). Bethesda, American Society of Physiology, 1991, pp 323-336.
38. Marks J, Srai SK, Biber J, Murer H, Unwin RJ, Debnam ES: Intestinal phosphate absorption and the effect of Vitamin D: a comparison of rat with mouse. Exp Physiol 2006;91:531-537.
39. Wrong O, Metcalfe-Gibson A, Morrison RBI, Ng ST, Howard AV: In vivo dialysis of faeces as a method of stool analysis. 1. Technique and results in normal subjects. Clin Sci 1965;28:357-375.
40. Daum K, Tuttle WW, Kisgen R, Imig CJ, Martin C, Klapka MR, Sheehan J, Agle M: Utilization of nitrogen, phosphorus, calcium and iron by men on different breakfasts. J Am Diet Ass 1951;27:475-479.
41. Shohl AT: Mineral Metabolism, New York, Reinhold, 1939.
42. Sullivan JF, O'Grady J, Lankford HG: The zinc content of pancreatic secretion. Gastroenterology 1965;48:438-443.
43. Grove EW, Olmsted WH, Koenig K: The effect of diet and catharsis on the lower volatile fatty acids in the stools of normal men. J Biol Chem 1929;85:127-136.
44. Rubinstein R, Howard AV, Wrong OM: In vivo dialysis of faeces as a method of stool analysis. 4. The organic anion component, Clin Sci 1969;37:549-564.
45. Wrong OM, Edmonds CJ, Chadwick VS: The Large Intestine. Its Role in Mammalian Nutrition and Homeostasis. Lancaster, MTP Press, 1981.
46. Costongs GMPJ, Bos LP, Engels LGJB, Janson PCW: A new method for chemical analysis of faeces. Clin Chim Acta 1985;150:197-203.
47. Drasar BS, Hill MJ: Human Intestinal Flora. London, Academic Press, 1974.
48. Wilson DR, Ing TS, Metcalfe-Gibson A, Wrong OM: The chemical composition of faeces in uraemia, as revealed by in-vivo faecal dialysis. Clin Sci 1968;35:197-209.
49. Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, Schaedler REW, Gordon SJ: Bacterial populations of the small intestine in uremia. Nephron 1978;22:63-68.
50. Franks F: Aqueous solutions of electrolytes; in Franks F (ed): Water. London, Royal Society of Chemistry, 1983, pp 57-68.
51. Diamond RM, Whitney DC: Resin selectivity in dilute to concentrated systems; in Marinsky JA (ed): Ion Exchange: A Series of Advances, vol 1. London, Arnold, 1966, pp 277-351.
52. Feitelson J: Interaction between organic ions and ion exchange resins; in Marinsky JA (ed): Ion Exchange: A Series of Advances, vol 2. New York, Dekker, 1969, pp 135-166.
53. Katchalsky A, Michaeli I: Polyelectrolyte gels in salt solutions. J Polym Sci 1955;15:69-86.
54. Clifford D, Weber WJ: The determinants of divalent/monovalent selectivity in anion exchangers. Reactive Polym 1983;1:77-89.
55. Dorfner K: Ion exchangers in pharmacy and medicine; in Coers AF (ed): Ion Exchangers: Properties and Applications. Michigan, Ann Arbor Science, 1972, pp 227-236.
56. Parkinson TM, Gundersen K, Nelson NA: Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum cholesterol in experimental animals and man. Atherosclerosis 1970;11:531-537.
57. Ryan JR, Jain A: The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a long-term controlled study. J Clin Pharmacol 1972;12:268-273.
58. Tilsley GM: Interactions of organic matter with anion resins. Chem Ind 1979;5:142-149.
59. Homma Y, Kobayashi T, Yamaguchi H, Ozawa H, Sakane H, Nakamura H: Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinaemia. Atherosclerosis 1997;129:241-248.
60. Date T, Shigematsu T, Kawashima Y, Satake N, Morita K: Colestimide can be used as a phosphate binder to treat uraemia in end stage renal disease patients. Nephrol Dial Transplant 2003;18(suppl 3):90-93.
61. Kurihara S, Tsuruta Y, Akizawa T: Effect of MCI-196 (colestilan) on hyperphosphataemia in haemodialysis patients: a double-blind placebo-controlled, short-term trial. Nephrol Dial Transplant 2005;20:424-430.
62. Burt HM, Cameron EC, Leung M, Erber H, Price JDE: In vitro studies using ion exchange resins as potential phosphate binders in renal failure patients. Uremia Invest 1985-86;9:35-44.
63. Burt HM, Cameron EC, Erber H, Price JDE: Ion-exchange resins as potential phosphate-binding agents for renal failure patients: effect of the physicochemical properties of resins on phosphate and bile salt binding. J Pharm Sci 1987;76:379-383.
64. Inoue H, Kagoshima M, Kaibara K: Effects of anion exchange resin as phosphate binder on serum phosphate and iPTH levels in normal rats. Int J Artif Organs 2000;23:243-249.
65. Cummings JH, Jenkins DJA, Wiggins HS: Measurement of the mean transit time of dietary residue through the human gut. Gut 1976;17:210-218.
66. Evans RC, Kamm MA, Hinton JM, Lennard-Jones JE: The normal range and a simple diagram for whole gut transit time. Int J Colorect Dis 1992;7:15-17.
67. Braun J, Asmus H, Brunkhorst R, Krause R, Schutz W, Neumayer H, Raggi P, Bommer J: Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-116.
68. Emmett M: A comparison of clinically useful phosphorus binders for patients with chronic kidney disease. Kidney Int 2004;66(suppl 90):S25-S32.
69. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance dialysis. Kidney Int 2005;67(suppl 95):S13-S20.
70. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
71. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effect of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
72. Hergesell O, Ritz E: Phosphate binders in uraemia: the pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 2002;17:14-17.
73. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
74. Borras M, Marco MP, Fernandez E: Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002;22:737-738.
75. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E: Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002;92:499-500.
76. Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66(suppl 90):S39-S45.
77. Sonikian MA, Pani IT, Hiopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA: Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated with sevelamer hydrochloride. Ren Fail 2005;27:143-147.
78. Wrong OM, Harland CE: Sevelamer-induced acidosis. Kidney Int 2005;67:776-777.
79. Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK: Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 2006;16:248-252.
80. Vogel AI: A Textbook of Quantitative Inorganic Analysis Including Elementary Instrumental Analysis, ed 3. London, Longmans, 1961.
81. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM: Effect of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing dialysis. Arthritis Rheum 2005;52:290-295.
82. Nikolov IG, Joki N, Maizel J, Lacour B, Drüeke TB, Massy ZA: Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl 2006;105:S16-S23.
83. Merck Index, ed 14. Whitehouse Station, Merck and Co., 2006.
84. Reifenstein FC, Albright F, Wells SL: The accumulation, interpretation, and presentation of data pertaining to metabolic balances, notably those of calcium, phosphorus and nitrogen. J Clin Endocrinol 1945;5:367-395.
85. Chugh KS, Swales JD, Brown CL, Wrong OM: Aluminium resin for the treatment of the hyperkalaemia of renal failure. Lancet 1968;ii:952-953.